ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lai, W.-W.
Right arrow Articles by Chen, F.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lai, W.-W.
Right arrow Articles by Chen, F.-F.

Ann Thorac Surg 1996;62:1500-1504
© 1996 The Society of Thoracic Surgeons

Original Article: General Thoracic

Immunohistochemical Analysis of nm23-H1 in Stage I Non–Small Cell Lung Cancer: A Useful Marker in Prediction of Metastases

Wu-Wei Lai, MD, Ming-Ho Wu, MD, Jing-Jou Yan, MD, Feng-Feng Chen, MD

Division of Thoracic Surgery, Departments of Surgery and Pathology, National Cheng Kung University Hospital, Taiwan, Republic of China

Accepted for publication June 15, 1996.

Background. About 30% to 40% of patients with pathologic stage I non–small cell lung cancer die within 5 years after complete resection. The identification of subgroups with high risk of recurrence is important. The level of nm23-H1/nucleoside diphosphate kinase expression has been reported to correlate inversely with the metastatic potential of some tumors.

Methods. We examined immunohistochemically the expression of nm23-H1 in 32 stage I non–small cell lung cancers to determine its value in predicting the outcome of the operation.

Results. Twelve (37.5%) recurrences and ten deaths occurred in this series. There were eight (25%) distant and four (12.5%) locoregional recurrences. Of the 32 pathologic stage I non–small cell lung cancers, 10 (31.3%) were positive for nm23-H1 gene product. None of the patients with a higher nm23-H1 protein level had detectable distant metastases at the end of this study ({chi}2 test, p < 0.05). The median follow-up time to date is only 35 months (range, 18 to 83 months), and so far no significant difference in overall survival rate has been observed between the groups with high and low nm23-H1 protein levels.

Conclusions. The level of nm23-H1 protein is more useful than the T status or histologic type for the prediction of distant metastases, whereby cases may be selected for postoperative adjuvant chemotherapy.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
H. Katakura, F. Tanaka, H. Oyanagi, R. Miyahara, K. Yanagihara, Y. Otake, and H. Wada
Clinical significance of nm23 expression in resected pathologic-stage I, non-small cell lung cancer
Ann. Thorac. Surg., April 1, 2002; 73(4): 1060 - 1064.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
A N J Graham, P Maxwell, K Mulholland, A H Patterson, N Anderson, K G McManus, H Bharucha, and J A McGuigan
Increased nm23 immunoreactivity is associated with selective inhibition of systemic tumour cell dissemination
J. Clin. Pathol., March 1, 2002; 55(3): 184 - 189.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.